TheScreener - Chemical Works of Gedeon Richter Plc (RICHTER) RICHTER GEDEON reduced its risk exposure resulting in an upgrade to Slightly Positive

Report

TheScreener

EUR 13.91 For Business Accounts Only

RICHTER GEDEON reduced its risk exposure resulting in an upgrade to Slightly Positive

RICHTER GEDEON (DE), a company active in the Pharmaceuticals industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date February 18, 2022, the closing price was EUR 22.32 and its potential was estimated at EUR 25.81.

19/02/2022 1 EN

Underlying

Chemical Works of Gedeon Richter Plc

Chemical Works of Richter Gedeon is a multinational pharmaceutical company that is engaged in the research, development, production and marketing and trade of pharmaceutical products. Co.'s activities are divided into two major business segments: Pharmaceutical, including research, development and manufacturing of pharmaceutical products; and Wholesale and Retail including wholesale and retail trade through the distribution chain as well as marketing of its products. Co. is primarily engaged in production of gynecological, cardiovascular and gastroenterological products, antibiotics, antimicotics, OTC and medicines for treatment of the central nervous system.

See profile

HU0000123096 Budapest Stock Exchange Hungary

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Concorde Securities

Impressive guidance in line with our estimates

Richter posted clean EBIT of HUF 59.1bn (+18% YoY) on net sales of HUF 203.2bn(-9% YoY) for Q4/23. Clean EBIT was 36% ahead of the consensus estimate of HUF43.5bn and our estimate of HUF 43.4bn, respectively, while net revenue beatestimate significantly. As a result, clean EBIT (incl. extra taxes) margin stood at29.2% compared to our estimate of 23.7%.

PREMIUM

March 4, 2024 March 4, 2024 4 EN

Concorde Securities

More than a single drug company

This is a transfer of coverage as after 30 years of equity research at ConcordeSecurities, Attila Vago left the Company. In line with our previous approach, we are still eager to evaluate Richter with a sum-of-thepartsmethod. We find this very important in case of Richter, as it consists of four wellseparated segments with different prospects and profitability. These are the Women’sHealthcare (WHC), the Neuropsychiatry (CNS or central nervous system), theBiotechnology (BIO) and the General Medicine (GM) segments. Our 12m ex-div TP is set at 12,990 HUF/sh, implying a 46% total return upsidepo...

PREMIUM

February 5, 2024 February 5, 2024 17 EN

Concorde Securities

Q3 results were strong despite FX headwinds and extra taxes

Richter posted clean EBIT of HUF 49.4bn (-24% YoY) on net sales HUF 188.5bn (-13% YoY) for Q3/23. Clean EBIT was 8% ahead of the consensus estimate of HUF 45.8bn and our estimate, respectively, while net revenue was broadly in line with both the consensus forecast of HUF 191.3bn and our estimate. As a result, clean EBIT (incl. extra taxes) margin stood at 19.8% compared to consensus estimate of 26.2% (-350bps YoY) and was better than the consensus estimate of 23.9%. In Q3 Richter recorded HUF 9.6bn extra tax levied on the pharmaceutical industry. Clean net income came in at HUF 54.6bn (-34% Y...

PREMIUM

November 13, 2023 November 13, 2023 5 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

RICHTER GEDEON reduced its risk exposure resulting in an upgrade to Slightly Positive

Empowering Investors

Impressive guidance in line with our estimates

More than a single drug company

Q3 results were strong despite FX headwinds and extra taxes

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe